Uncategorized

BioMarin drug acquired in buyout misses goal in rare disease study

Published

on

Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects. 

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version